Semaglutide and Cardiovascular risk: SUSTAIN 6 trial Summary: The SUSTAIN 6 trial looked at the cardiovascular outcomes (cardiovascular death, heart attack and stroke) in high cardiovascular risk diabetic patients being treated with semaglutide (Ozempic) versus placebo- with the results showing a significant 26% reduction in cardiovascular death, heart attack and stroke in patients being treated with semaglutide (Ozempic)
Based on preclinical studies, a systematic review of the neuroprotective mechanisms of GLP-1RA-based therapy in ischemic stroke [67] has shown that administration of drugs of this family before, during, or after an experimental stroke in animals with and without diabetes modulates an acute inflammatory response secondary to brain ischemia, reducing inflammation, endothelial dysfunction and excitotoxicity, as well as decreasing oxidative stress and apoptosis
Digital healthcare has brought new dimensions to health facilities, and telehealth solutions have proved to be one of the most efficient approaches to weight reduction
Calms inflammation and supports lining repair
Zhang W, Li W, Zhang C, Zhu C, Yi X, Zhou Y, et al
The United States Department of Agriculture (USDA) closely regulates the use of organic labeling on food packages